Alexion Aims To Drive PNH Diagnoses (And Soliris Sales) With Diagnostic
This article was originally published in Pharmaceutical Approvals Monthly
Alexion believes the challenge of identifying new patients with the "ultra-orphan" blood disorder paroxysmal nocturnal hemoglobinuria who are candidates for the company's biologic Soliris (eculizumab) will be helped by diagnostic technology recently in-licensed by the firm
You may also be interested in...
Alexion's C5 complement inhibitor Soliris (eculizumab) clears FDA March 16 for treatment of the orphan blood disorder paroxysmal nocturnal hemoglubinuria. The biologic carries a wholesale acquisition cost of $389,000 per year. Alexion is launching the product with a treatment support service (titled OneSource) with case managers to help facilitate reimbursement. During a March 26 conference call, President David Keiser maintained that "this cost is comparable to the cost of other medicines for disabling and life-threatening ultra-orphan diseases, which are often dosed by weight." Alexion, however, is not resting on its laurels with the PNH claim: the firm is running the EXPLORE patient identification program for blood cell production disorders and recently said it is considering a similar program for the thrombosis market (1Pharmaceutical Approvals Monthly March 2007, p. 4)...
FDA reviewers stuck to established assessment practices during the coronavirus crisis and produced one of the agency’s largest yearly novel approval counts ever.
Spironolactone TOPCAT Regional Analysis Falls Short At US FDA AdComm, But Hospitalizations Drive Vote
A new indication for the generic diuretic in heart failure with preserved ejection fraction gets an 8-4 vote, with one abstention, despite troubles an analysis that tries to revive the TOPCAT trial with an analysis excluding Eastern European sites – or about half the participants.